Zuckerberg and Chan’s Biohub Pours $1.8 Billion Into AI That Simulates Human Cells

Published 9 October 2026 · Updated 19 October 2026

The most ambitious AI project you have not heard about is not building the next chatbot or reasoning model. It is building a virtual human cell.

Mark Zuckerberg and Priscilla Chan’s science nonprofit, Biohub, just expanded its Virtual Biology Initiative from $500 million into a $1.8 billion effort (a headline figure that includes previously committed money and existing federally funded data) backed by the US government, Google DeepMind, and Meta. The goal: collect enough cellular data to train AI that can simulate how human cells behave.

If it works, drug discovery changes forever. You test medicines on software before you ever touch a petri dish.

A universal virtual cell

Biohub’s end game is something they call the “universal virtual cell” – AI software that predicts how a cell will respond to a drug, a toxin, or a genetic change before any lab work begins. Think of it as a digital twin for the basic unit of human biology.

The National Institutes of Health is contributing datasets built on more than $500 million in past federal spending. The US Department of Energy is committing another $500 million over five years. Google DeepMind and Meta are chipping in $300 million alongside Isomorphic Labs, the drug discovery startup Demis Hassabis co-founded. All three private partners keep the resulting data private for a year before releasing it publicly.

Biohub’s head of science, Alex Rives, says accurate models will need data from trillions of cells. The biggest existing datasets cover only hundreds of millions. By Rives’s own estimate, Biohub is orders of magnitude short of what it needs — which is exactly why this partnership exists in the first place.

Why this matters

Fresh off AI making headlines by cracking open problems in pure mathematics, you might wonder which field the technology comes for next. Zuckerberg and Chan are making biology the target. They are throwing money, datasets, and talent at a moonshot that Biohub itself frames as “cure or prevent all disease.”

That language is ambitious enough to sound naive. But the structure here is worth paying attention to. This is not a single lab chasing a breakthrough. It is a coordinated effort between government agencies, big tech companies, and a well-funded nonprofit, all pointed at the same bottleneck: we do not have enough cellular data to train capable biological AI.

The private data exclusivity period is the detail that stands out. DeepMind, Meta, and Isomorphic Labs get first access to the data they help generate, a full year before it becomes public. That is a significant commercial advantage for companies already dominant in AI. Whether that arrangement accelerates or distorts the science is a question worth watching.

The bigger picture

Biohub’s virtual cell is part of a broader pattern. The largest AI investments are no longer about language or images. They are about building simulators of the physical world — weather, protein folding, cellular biology, materials science. Each one requires enormous amounts of domain-specific data, and each one has the potential to transform an entire industry.

The universal virtual cell may or may not arrive. But the machinery being built to pursue it — the datasets, the partnerships, the infrastructure — will produce useful science regardless. That is the quiet genius of projects like this: the attempt itself moves the field forward.

Sources

Analysis and opinion are the author’s. Factual statements are attributed to the sources above.

How this analysis is researched, sourced and corrected: Editorial standards and corrections. Spotted an error? Contact Philip Hall.

Subscribe

Related articles

The UK Just Narrowly Avoided a Fridge Hack. The Rest of the World Isn’t So Lucky.

A secret operation that spanned supermarkets, warehouses and stadiums In...

AI Agents Are Trading Secrets for Help. That Is a Security Architecture Problem

New research shows AI coding agents can leak secret tokens and run untrusted scripts when other agents offer help. The lesson is architectural: keep secrets out of agent runtime.

AI Agents Are Hunting Exposed Secrets, and Businesses Are Exposed

Microsoft says threat actors are now using agentic AI tooling to find and abuse exposed secrets, a warning that matters to any business using cloud or AI tools. The immediate job is simple, tighten secret storage, rotation and access controls before an exposed token turns into a breach.

CrowdStrike’s AI Agent Kill Switch Is a Sign of the Times

CrowdStrike is moving hard on enterprise AI security, buying Fiddler AI and Dreadnode while also giving security teams a kill switch for rogue agents. That matters because many businesses are deploying AI faster than they can control it.
Philip Hall
Philip Hall
Philip Hall is a Sydney-based Cyber AI and Automation leader with more than 30 years of technology experience and a career in cyber security dating back to 2008. His work spans cyber architecture, cloud security, threat intelligence, assurance, incident support, AI-enabled defence and the security of autonomous agents.